Cassava Sciences’ year-to-date stock performance.
Cassava Sciences: “They do have an Alzheimer’s trial, but Lilly has an Alzheimer’s formulation that is very good. And Lilly does have the edge on everybody else.”
Mobileye Global’s year-to-date stock performance.
Mobileye Global: “…I think it’s just too hard to tell, I’m going to stay away from it.”
